Olon Group has strengthened its CDMO capabilities with the acquisition of GTP Bioways Group, a French company operating as Biotech CDMO and specializing in R&D services, process development and production of mAbs, enzymes, proteins, nanodrugs, ADCs and fill-finish.

GTP Bioways operates a total of four sites in France (Toulouse, Labege, Veyre-Monton, and Saint-Julien-en-Genevois) focused on development, clinical trial and cGMP manufacturing. The headquarters are based in Toulouse.

“The acquisition of GTP Bioways Group implies a strong and significant strengthening of Olon’s service pipeline with the aim of creating new business opportunities, acquiring new customers and high-potential market areas, and ultimately continuing the company’s growth,” said Paolo Tubertini, CEO, Olon Group.

The business areas which GTP Bioways focuses on include biologics manufacturing and ADC manufacturing (using mammalian and microbial fermentation technology), nanodrug manufacturing, fill and finish and analytical development, including HCP and immuno assay. The CDMO services offered make up an integrated platform capable of supporting customers from drug discovery through the entire development process with a special focus on the pre-clinical phase, phase I and phase II.

In the third quarter of 2024, Olon will finalize its €25 million investment in a facility operating under extreme high containment, dedicated to the development and the production of ultra-high potent API payloads and payload-linkers for ADCs. Olon relies on more than four decades of experience in manufacturing cytotoxic products. With the acquisition of GTP Bioways, Olon Biotech will be able to offer full services for the development and production of ADCs, capable of supplying everything from mAbs to linkers, payloads, conjugation, and fill and finish.

“ADCs are highly promising and extremely challenging as well, as they require specific capabilities to handle different modalities with strict containment regulations,” said Tubertini. “This required high level of control ensures the safest environment for ADC payload-linker production and product integrity, that can only be reached leveraging over decades of expertise in containment for cytotoxic anticancer production, focusing on full control of cross-contamination, operator protection and extensive training.”